ALS 886

Drug Profile

ALS 886

Alternative Names: ALS-886

Latest Information Update: 06 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter International
  • Developer Advanced Life Sciences
  • Class Anti-inflammatories; Benzoic acids; Small molecules
  • Mechanism of Action Chelating agents; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Suspended Adult respiratory distress syndrome; Lung disorders
  • No development reported Brain oedema

Most Recent Events

  • 06 May 2011 Suspended - Preclinical for Adult respiratory distress syndrome in USA (unspecified route)
  • 06 May 2011 Suspended - Preclinical for Lung disorders in United Kingdom (unspecified route)
  • 17 Jul 2008 Preclinical trials in Lung disorders in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top